ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 9, 2023, Revance Therapeutics, Inc. (the "Company") issued a press release, which provided a DAXXIFY® commercial launch update, the expected range of revenue from sales of DAXXIFY® for the three months ended December 31, 2022 and the RHA® Collection of dermal fillers and OPUL® and the HintMD fintech platform for the three months and year ended December 31, 2022, the Company's cash balance as of December 31, 2022 and the Company's expectations for U.S. generally accepted accounting principles ("GAAP") and non-GAAP operating expenses for the year ended December 31, 2022, each on a preliminary and unaudited basis. These are preliminary estimates based on currently available information and do not present all necessary information for a complete understanding of the Company's financial condition as of December 31, 2022, or the Company's results of operations for the year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in such filing.

ITEM 8.01 OTHER EVENTS On January 6, 2023, the Company announced that the U.S. Food and Drug Administration (the "FDA") accepted its Biologics License Application with respect to DAXXIFY® (DaxibotulinumtoxinA-lanm) for the treatment of cervical dystonia. The Company was provided a Prescription Drug User Fee Act (PDUFA) date of August 19, 2023.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS



(d) Exhibits

Number         Description
  99.1           Press Release dated January 9, 2023
104            Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses